Observational Study of Intranasal IVIG in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Patients Undergoing Medical Tourism

This observational study is being conducted by Healing Hope International to collect real-world data on an emerging treatment approach for Long COVID in patients with immunodeficiency. The study investigates the effects of intranasal immunoglobulin (IVIG) therapy in a real-world setting. Participants will be individuals diagnosed with Long COVID who have confirmed immunodeficiency, such as low IgG or IgA levels or specific antibody deficiency. These individuals are receiving care through international clinical programs and will not receive any treatment as part of this study. Instead, Healing Hope will collect health information, clinical outcomes, and laboratory results from participating sites to better understand how intranasal IVIG might help reduce symptoms such as fatigue, brain fog, inflammation, and immune dysregulation. The goal of this study is to contribute new insights into potential treatment options for Long COVID and to support responsible, science-backed care models for patients participating in medical tourism. No experimental drugs are being administered as part of this protocol. All treatment decisions are made independently by each clinical site. Data will be anonymized and used to advance knowledge in the field of immunological recovery and neuroinflammation.

NCT Number	NCT06992401
Lead Sponsor	Tamara C Tamas
Conditions	Post-Acute Sequelae of SARS-CoV-2 Infection, Long COVID, Long COVID Fatigue, Long COVID Syndrome, COVID 19 Associated Coagulopathy, COVID-19 Vaccination
Enrollment	50 participants
Start Date	2026-08-01
Primary Completion	2029-01-01 (estimated)
Study Completion	2029-07-15 (estimated)
Updated on ClinicalTrials.gov	2025-12-02